설파피리딘
설파피리딘 · Sulphapyridine · Sulfapyridin · THAP11 · 4-AMINO-N-[2-PYRIDYL]BENZENE SULFONAMIDE · 2-hydroxybenzenecarboxylic acid (salicylic acid) · Ronin · A-499
식별자 및 물리적 특성
| CAS No. | 144-83-2 |
|---|---|
| 분자식 | C11H11N3O2S |
| 평균 분자량 | 249.29 g/mol |
| 단동위원소 질량 | 249.05719778 g/mol |
| SMILES | Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1 |
| InChIKey | GECHUMIMRBOMGK-UHFFFAOYSA-N |
| PubChem CID | 5336 |
| ChEMBL | CHEMBL700 |
| ChEBI | CHEBI:132842 |
| EC No. | 205-642-7 |
| DTXSID | DTXSID3026067 |
| 현지명 | 설파피리딘 |
화학 및 물리적 성질
| XLogP | 0 |
|---|---|
| 극성 표면적 | 93.5 |
| 수소 결합 공여자 수 | 2 |
| 수소 결합 수용자 수 | 5 |
| 회전 가능 결합 수 | 3 |
| 무거운 원자 수 | 17 |
| 형식 전하 | 0 |
| 복잡도 | 331 |
| 녹는점 | 191-193°C |
| 끓는 점 | 473.5±51.0 °C(Predicted) |
| 밀도 | 1.3220 (rough estimate) |
| 굴절률 | 1.6740 (estimate) |
| 저장 조건 | Keep in dark place,Sealed in dry,Room Temperature |
| 용해도 | DMSO(약간 용해됨), 메탄올(약간 용해됨) |
| 물리적 상태 | Solid |
| pKa(산도 계수) | pKa 8.48(H2O t = 25 I = 0.05) (Uncertain) |
| 색상 | 흰색에서 황백색까지 |
| 용해도 | 22&C에서 <0.1g/100mL |
| Merck | 14,8938 |
| BRN | 222065 |
| 안정성 | 안정적인. 타기 쉬운. 빛으로부터 보호하십시오. 강한 산화제와 호환되지 않습니다. |
| 주요 응용 | 법의학 및 독성학의약품(소분자) |
| InChI | 1S/C11H11N3O2S/c12-9-4-6-10(7-5-9)17(15,16)14-11-3-1-2-8-13-11/h1-8H,12H2,(H,13,14) |
| InChIKey | GECHUMIMRBOMGK-UHFFFAOYSA-N |
| SMILES | Nc1ccc(cc1)S(=O)(=O)Nc2ccccn2 |
| NIST | Sulfapyridine(144-83-2) |
| EPA | Sulfapyridine (144-83-2) |
화학적 성질
White to Off-White Solid
안전 및 규제
| 수질 위해 등급(WGK) | 2 |
|---|---|
| TSCA 등재 상태 | TSCA listed |
| RTECS 번호 | DA9625000 |
| 독성 | LD50 orally in mice: 7.5 mg/g (Wien) |
| 관세 코드 | 29350010 |
| 위험 문구(R) | 36/37/38 |
| 위험 표시 | Xi |
| 안전 문구(S) | 22-24/25-36-26 |
| 위험 등급 | IRRITANTRepr. 2 |
| 저장 분류 | 11 - Combustible Solids |
용도
개요
Sulfapyridine is a sulfonamide antibiotic with antibacterial and anti-inflammatory activities. It is also a metabolite of sulfasalazine formed through bacterial conversion in the colon. It is active against strains of Y. enterocolitica and Salmonella (MICs = 3.1-25 and 25-100 μg/ml, respectively), as well as S. aureus (MBC = 0.8 μM). It is an inhibitor of recombinant P. carinii dihydropteroate synthetase (DHPS; IC50 = 0.18 μM). Sulfapyridine scavenges peroxyl radicals in an oxygen radical absorbance capacity (ORAC) assay. It inhibits histamine release induced by compound 48/80 from isolated rat peritoneal mast cells in a dose-dependent manner. Sulfapyridine (1 μg/kg) also inhibits compound 48/80-induced systemic allergic reaction in rats. Formulations containing sulfapyridine have previously been used in the treatment of dermatological conditions and ulcerative colitis.
용도
Used in treatment of dermatitis herpetiformis; antibacterial.
일반 설명
Sulfapyridine’s plasma half-life is 9 hours.This compound is a white, crystalline, odorless, and tastelesssubstance. It is stable in air but slowly darkens on exposureto light. It is soluble in water (1:3,500), in alcohol(1:440), and in acetone (1:65) at 25°C. It is freely soluble indilute mineral acids and aqueous solutions of sodium andpotassium hydroxide. The pKa is 8.4. Its outstanding effectin curing pneumonia was first recognized by Whitby; however,because of its relatively high toxicity, it has been supplantedlargely by sulfadiazine and sulfamerazine. Severalcases of kidney damage have resulted from acetylsulfapyridinecrystals deposited in the kidneys. It also causes severenausea in most patients. Because of its toxicity, it is usedonly for dermatitis herpetiformis.Sulfapyridine was the first drug to have an outstandingcurative action on pneumonia. It gave impetus to the studyof the whole class of N1 heterocyclically substituted derivativesof sulfanilamide.